In the phase I JAVELIN Hodgkin trial (NCT02603419), the PD-L1 inhibitor avelumab had an ORR of 55% and CR of 7%, further demonstrating that inhibiting the PD-1/PD-L1 axis is effective in HL [91]. The gene discussed is CD274; the disease is Hodgkins lymphoma.